JoVE Logo
Faculty Resource Center

Sign In

Production of Human CRISPR-Engineered CAR-T Cells

DOI :

10.3791/62299-v

March 15th, 2021

March 15th, 2021

10,776 Views

1Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, 2Parker Institute for Cancer Immunotherapy, University of Pennsylvania

Here, we present a protocol for gene editing in primary human T cells using CRISPR Cas Technology to modify CAR-T cells.

-- Views

Related Videos

article

In Vitro Differentiation of Human CD4+FOXP3+ Induced Regulatory T Cells (iTregs) from Naïve CD4+ T Cells Using a TGF-β-containing Protocol

article

Activation and Conjugation of Soluble Polysaccharides using 1-Cyano-4-Dimethylaminopyridine Tetrafluoroborate (CDAP)

article

Adjuvant Activity of Mycobacterium paratuberculosis in Enhancing the Immunogenicity of Autoantigens During Experimental Autoimmune Encephalomyelitis

article

Author Spotlight: Studying Host-Microbe Interactions in Wound Biofilm Formation

article

Author Spotlight: Expanding the Scope of Multiplex Immunoassays for Lyme Borreliosis Diagnostics and Pathogen Research

article

Author Spotlight: Neutrophil Extracellular Traps Imaging in Human and Mouse Tissues

article

Author Spotlight: Dendritic Cells Maturation Using Sialidases-Based Enzymatic Treatment of the Cell Surface

article

Monocyte Isolation and Monocyte Differentiation into Monocyte-Derived Dendritic Cells

article

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

article

Preparing Slides of CVS-11 Virus Antigen for Detecting Rabies-Specific Antibodies

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved